JP2023508173A5 - - Google Patents
Info
- Publication number
- JP2023508173A5 JP2023508173A5 JP2022539175A JP2022539175A JP2023508173A5 JP 2023508173 A5 JP2023508173 A5 JP 2023508173A5 JP 2022539175 A JP2022539175 A JP 2022539175A JP 2022539175 A JP2022539175 A JP 2022539175A JP 2023508173 A5 JP2023508173 A5 JP 2023508173A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody according
- antibody
- seq
- cancer
- fgfr2b
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019127903 | 2019-12-24 | ||
| CNPCT/CN2019/127903 | 2019-12-24 | ||
| PCT/CN2020/138591 WO2021129656A1 (en) | 2019-12-24 | 2020-12-23 | Novel anti-fgfr2b antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023508173A JP2023508173A (ja) | 2023-03-01 |
| JP2023508173A5 true JP2023508173A5 (enExample) | 2024-01-05 |
| JP7686000B2 JP7686000B2 (ja) | 2025-05-30 |
Family
ID=76573701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539175A Active JP7686000B2 (ja) | 2019-12-24 | 2020-12-23 | 新規抗ＦＧＦＲ２ｂ抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230052256A1 (enExample) |
| EP (1) | EP4081539A4 (enExample) |
| JP (1) | JP7686000B2 (enExample) |
| KR (1) | KR20220119143A (enExample) |
| CN (1) | CN114901687A (enExample) |
| AR (1) | AR120884A1 (enExample) |
| AU (1) | AU2020410863A1 (enExample) |
| CA (1) | CA3160811A1 (enExample) |
| MX (1) | MX2022007960A (enExample) |
| TW (1) | TWI861325B (enExample) |
| WO (1) | WO2021129656A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023243773A1 (en) * | 2022-03-28 | 2024-10-24 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Novel anti-fgfr2 antibodies. |
| CN117917435A (zh) * | 2022-10-21 | 2024-04-23 | 北京天广实生物技术股份有限公司 | 结合fgfr2b的抗体及其用途 |
| WO2024199362A1 (en) * | 2023-03-31 | 2024-10-03 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Novel anti-FGFR2 antibodies |
| CN118994393A (zh) * | 2023-05-19 | 2024-11-22 | 广东东阳光药业股份有限公司 | 一种抗fgfr2抗体及其应用 |
| WO2025146131A1 (en) * | 2024-01-05 | 2025-07-10 | Beigene, Ltd. | ANTI-FGFR2b ANTIBODIES, CONJUGATES AND METHODS OF USE |
| CN121319178A (zh) * | 2024-07-02 | 2026-01-13 | 安博泰克药业有限公司 | 特异性结合FGFR2b的抗体及其与药物的缀合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1012259E (pt) * | 1997-06-04 | 2009-11-06 | Oxford Biomedica Ltd | Vector dirigido a tumor |
| MXPA05009556A (es) * | 2003-03-14 | 2005-11-16 | Wyeth Corp | Anticuerpos contra receptor de il-21 humano y sus usos. |
| AU2003271174A1 (en) * | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| SI1680140T1 (sl) * | 2003-10-16 | 2011-08-31 | Imclone Llc | Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi |
| US7371825B2 (en) * | 2004-06-30 | 2008-05-13 | Centocor, Inc. | Anti-MCP-1 antibodies, compositions, methods and uses |
| US8101721B2 (en) * | 2006-06-15 | 2012-01-24 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| DK3290052T3 (da) * | 2008-11-07 | 2020-02-03 | Galaxy Biotech Llc | Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2 |
| JP2014534806A (ja) * | 2011-08-23 | 2014-12-25 | ロシュ グリクアート アーゲー | 抗ｍｃｓｐ抗体 |
| AR088941A1 (es) * | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| MX2014007121A (es) * | 2011-12-14 | 2014-09-04 | Seattle Genetics Inc | Nuevos conjugados de principio activo-ligante (adc) y su uso. |
| MX374785B (es) * | 2013-08-01 | 2025-03-06 | Five Prime Therapeutics Inc | Anticuerpos anti-fgfr2iiib afucosilados. |
| CA2961439A1 (en) * | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| SG10201913538VA (en) * | 2015-11-23 | 2020-02-27 | Five Prime Therapeutics Inc | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
| US20170145086A1 (en) * | 2015-11-25 | 2017-05-25 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| IL266769B2 (en) * | 2016-11-22 | 2024-04-01 | Merck Patent Gmbh | Monoclonal antibodies specific for fgfr1 and their preparation |
| WO2018095932A1 (en) * | 2016-11-22 | 2018-05-31 | Merck Patent Gmbh | Monoclonal antibody directed to fgfr1 |
| CN114846029A (zh) * | 2019-12-24 | 2022-08-02 | 迪哲(江苏)医药股份有限公司 | 新颖抗fgfr2b抗体 |
| JP7685999B2 (ja) * | 2019-12-24 | 2025-05-30 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | 新規抗ＦＧＦＲ２ｂ抗体 |
-
2020
- 2020-12-23 AR ARP200103629A patent/AR120884A1/es unknown
- 2020-12-23 JP JP2022539175A patent/JP7686000B2/ja active Active
- 2020-12-23 KR KR1020227025531A patent/KR20220119143A/ko active Pending
- 2020-12-23 CN CN202080089840.3A patent/CN114901687A/zh active Pending
- 2020-12-23 WO PCT/CN2020/138591 patent/WO2021129656A1/en not_active Ceased
- 2020-12-23 CA CA3160811A patent/CA3160811A1/en active Pending
- 2020-12-23 MX MX2022007960A patent/MX2022007960A/es unknown
- 2020-12-23 AU AU2020410863A patent/AU2020410863A1/en active Pending
- 2020-12-23 US US17/788,730 patent/US20230052256A1/en active Pending
- 2020-12-23 EP EP20907461.6A patent/EP4081539A4/en active Pending
- 2020-12-24 TW TW109145974A patent/TWI861325B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023508174A5 (enExample) | ||
| JP2023509402A5 (enExample) | ||
| CN110627906B (zh) | 抗pd-l1/4-1bb双特异性抗体及其用途 | |
| JP7820383B2 (ja) | グリピカン－３およびｔ細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド | |
| ES2773504T3 (es) | Nuevo polipéptido que tiene afinidad por PD-L1 | |
| JP7821159B2 (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 | |
| JP2024001073A5 (enExample) | ||
| CA2959671C (en) | Anti-ck8 antibodies for use in the treatment of cancers | |
| CN121909212A (zh) | 抗cdh17抗体及其用途 | |
| CN119173540A (zh) | 多特异性抗体及其用途 | |
| EP3418303A1 (en) | ANTIBODY AGAINST EGFRvIII AND USE THEREOF | |
| CA3208368A1 (en) | Vegfa-binding molecules | |
| AU2020326590A1 (en) | Materials and methods for polymeric antibody receptor targeting | |
| JP7821161B2 (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 | |
| JP2022505144A5 (enExample) | ||
| CN120271715A (zh) | 抗体及其药物偶联物和用途 | |
| CN112823168A (zh) | 结合her2的四聚体多肽 | |
| CN117304324A (zh) | 结合Claudin 18.2的结合部分及其应用 | |
| CN120379695A (zh) | 使用Multabody治疗化疗抗性肿瘤 | |
| WO2025117871A1 (en) | Bispecific tetravalent antibody targeting her2 and her3 | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof | |
| JP2024535691A5 (enExample) | ||
| CN116917331A (zh) | 包含靶向磷脂酰肌醇蛋白聚糖-3和t细胞受体的免疫球蛋白单可变结构域的多肽 | |
| CN118488971A (zh) | 优化的Multabody构建体、组合物和方法 | |
| CN116761887A (zh) | 靶向SIRPα和PD-L1的双特异性抗体 |